Amylin's Pramlintide/Metreleptin Combo Becomes The Latest Obesity Casualty
This article was originally published in The Pink Sheet Daily
Discontinuation is unrelated to prior safety suspension, say Amylin and Takeda, who acknowledge that "this is a difficult time for innovators and regulators."
You may also be interested in...
The Dec. 11 Endocrinologic and Metabolic Drugs Advisory Committee also will consider whether a proposed Risk Evaluation and Mitigation Strategy would address the possible risk for lymphoma and immunogenicity with Bristol-Myers Squibb/AstraZeneca’s drug.
Two decades ago, the “fat dissolving” protein leptin was touted as one of the biggest opportunities in biotech—based on preclinical rodent studies. The compound may finally be making it to market in a very different model: as an orphan drug sponsored by Big Pharma.
Appropriations Committee considers obesity a "significant unmet medical need."